I'm really looking forward to this talk!
Signup in the linked tweet.
(east coasters, note the GMT time zone!)

Anna Kaltenboeck Tim Anderson Audrey D. Zhang (@audreydzhang.bsky.social) Dan hartung Colleen Carey Kosuke Inoue Yusuke Tsugawa Jing Li JeahJung Stacie Dusetzina Genevieve Kanter, PhD

Sigh. Brand-name drug makers shouldn’t get “credit” for lower net prices due to generic and biosimilar competition.

Richard Evans should censor drugs with generic or biosimilar competition when assessing year-over year trends in brand-name drug prices.

statnews.com/pharmalot/2024…

I have news! I'm writing a book and W. W. Norton & Company has greed to publish it.

The book will tell the story of how the laws that we’ve adopted to keep government honest have stymied American progress. It'll come out in early 2026, god willing and the creek don't rise.

🚨🚨🚨
Our latest study is out this week in The Oncologist!

We looked at whether patients with commercial or Medicaid insurance are more likely to receive high-price (and hence, high-profit) chemotherapy treatments.

academic.oup.com/oncolo/advance…
🧵
1/

For any docs out there who struggle with prior auth and would love to have your biases confirmed, I highly recommend this new study by Michael Anne Kyle Nancy Keating, out yesterday in Journal of Clinical Oncology:

ascopubs.org/doi/full/10.12…
1/

Weekend reading JAMA : tinyurl.com/4v2hhyfb.

'Part D sponsors provided excessive point-of-sale reimbursements to pharmacies for certain generic drugs compared with acquisition costs.'

Inmaculada (Inma) Hernández Anna Kaltenboeck UW School of Pharmacy

Kudos to Colorado for scrutinizing cost of key drug | OPINION coloradopolitics.com/opinion/kudos-… via Colorado Politics

If you tuned in to Senate Finance Committee hearing yesterday, you probably heard Chairman Wyden, Senator Cassidy and Senator Cortez Maso asking me about a paper on generic reimbursement in Part D

This is the paper! Out in JAMA yesterday

jamanetwork.com/journals/jama/…

Medicare Negotiation And Innovation: A Response To O’Brien And Co-Authors | Health Affairs healthaffairs.org/content/forefr…

Weekend reading NEJM.

'TCET’s most notable feature may simply be that it is not MCIT, and it restores CMS’s role in device regulation.'

tinyurl.com/4jd3zhc7 Sean Tunis Anna Kaltenboeck Peter B. Bach, MD

The evidence is clear: Masks can reduce the risk of spreading Covid and of being infected with it. In a new review, my colleagues and I examined 40 studies on masks with seven different methodologies. Here’s what we found.

Masks play two roles—protecting the wearer and

$SRPT has been testing the boundaries of FDA evidence standards for pretty much its entire history. Looks like they have no plans to change strategies for confirmatory trials. It's sad for patients. And not a good look that this CEO drew a $124 million salary in 2022.

Alright #healthpolicy Twitter. In honor of Halloween, what’s your version of “the calls were coming from inside the house”?

Our new study is out today in The BMJ The BMJ!

Can receiving drug industry money lead oncologists to provide WORSE care?
The answer we found appears to be “yes”…

🧵 to follow
1/
bmj.com/content/383/bm…